Copyright
©The Author(s) 2025.
World J Psychiatry. Sep 19, 2025; 15(9): 109363
Published online Sep 19, 2025. doi: 10.5498/wjp.v15.i9.109363
Published online Sep 19, 2025. doi: 10.5498/wjp.v15.i9.109363
Table 2 Points for further consideration
Focus area | Action | Outcome measure |
Longitudinal efficacy | Behavioral tests + diffusion MRI at 2, 8, 16 weeks | Memory scores; fractional anisotropy |
Cell-type specificity | Generate CX3CR1-CreERT2 Hv1flox/flox for microglia-only KO; compare GFAP-Cre astrocyte KO | Cytokine levels; OPC survival; g-ratio |
Pharmacological proof-of-concept | Screen Hv1 inhibitors for IC50, BBB penetration, and toxicity; test alone and with remyelinating agents | Patch-clamp IC50; brain/plasma ratio; maze performance |
Mechanistic clarification | pH imaging in microglia under hyperglycemia; Co-IP of Hv1 and NOX2 | Intracellular pH; ROS assays; protein interaction |
- Citation: Li B. Microglial voltage-gated proton channel 1 ablation in diabetic mice mitigates diabetes-driven demyelination and cognitive decline. World J Psychiatry 2025; 15(9): 109363
- URL: https://www.wjgnet.com/2220-3206/full/v15/i9/109363.htm
- DOI: https://dx.doi.org/10.5498/wjp.v15.i9.109363